For philanthropy
Find, fund and follow through.
On the work that will cure, treat or prevent the disease you care about. The market that funds it doesn’t clear. Make it clear, and venture philanthropy starts to scale.
Checkpoint response in solid-tumour biopsies
We can see, cell by cell, which patients’ tumours the therapy actually reaches.→
The problem
Venture philanthropy doesn’t clear.
The capital, the willingness and the researchers all exist. The market doesn’t function.
01
Signal
You can’t tell who’s worth backing
The researcher knows what the work is worth. You see rank, publications and grant history. So the money follows reputation.
02
Coordination
Going together costs more than going alone
Every foundation runs its own diligence, structure and reporting. So everyone goes alone, and the capital is spread thin.
03
Nobody’s job
It would help everyone, so no one builds it
Every funder would use it. No single funder captures enough to pay for it.
Find · the field
Every project in your areas, in one place.
The platform holds the work in the fields you fund, whether or not it is funded and whether or not it has ever been put in front of you. You see the whole field before anyone brings it to you.
How it works
As easy as answering a question.
The researcher
Answers a question
No blank page. A question is waiting, and they answer it to camera. A minute between experiments.
We make it legible
The AI transcribes and pulls a headline quote. Their exact words, nothing invented, and they approve it before it posts.
You
Back it, together
Follow it, syndicate it, and stay across it as it matures. One deal, one record.
The middle step is the product. Without it, the other two never meet.
Find · your thesis
The work comes to you.
Publish what you fund and what you are looking for. Aligned work and aligned co-funders come to you, matched against your thesis, instead of you working the conference circuit for both.
Your thesis · published
What we’re hunting
You choose what is public. The thesis is the part of your strategy that works hardest when other people can read it.
Your pipeline, your numbers and who you are talking to stay private.
What comes back
A researcher
· Matched to your thesisAutoantibody screening in routine paediatric care. 1,200 children flagged at stage 1 this quarter.
A co-funder
· Funds the same workBacked two screening programmes last year. Open to leading the next round with you.
An institute
· Has the cohortRunning the clinic network your prevention thesis needs. Wants a conversation.
Every one of these is a conversation you did not have to start.
Fund · together
Lead the syndicate.
You set the coverage. Co-funders come onto one deal with the same memo, the same terms and the same diligence. The decision stays with each of you.
The round
Immune atlas · Series A
$3.0m / $3.0m
- YouLead · sets the terms$1.2m
- A disease foundationCommitted$900k
- A family officeCommitted$450k
- A research instituteIn diligence$450k
One round, one deal. Bilateral until they commit, so nobody sees who else is looking until you say so.
Diligence built once
The record, the memo and the questions are already there. You read the same pack, not your own from scratch.
One set of terms
Milestones, reporting and tranches are agreed on the deal, not renegotiated with each funder.
Co-funders you can find
See who else funds this kind of work and bring them in, rather than hoping to meet them at a conference.
Follow through · the book
Capital that proves itself.
Every opportunity you are working, weighted by likelihood and coverage. Once you commit, money moves as the work does. Milestones resolve from the deal itself, so you are not chasing a report to find out.
Watching
24
18% weighted
In diligence
9
42% weighted
Forming
4
71% weighted
Committed
6
100% weighted
Your track record builds as you deploy, so the next round is easier to raise than the last.
Find. Fund. Follow through.
Three jobs on one system. First signal to an outcome, and the decision stays yours.
On one system
Why Bright Arena
Proven. Built for scale.
10 years
Advising funders, institutes and philanthropic leaders.
$300m+
Directed into research.
1,000+
Researchers, from first lab to institute director.
Find it, fund it together, follow it through.
Start where you already lead. Prove the market clears in one disease, and it clears for the rest.
Bright Arena · Dougal Edwards · [email protected]